These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 19536068)

  • 1. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
    Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
    Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
    Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
    Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
    Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
    AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.
    Christensen MM; Pedersen RS; Stage TB; Brasch-Andersen C; Nielsen F; Damkier P; Beck-Nielsen H; Brøsen K
    Pharmacogenet Genomics; 2013 Oct; 23(10):526-34. PubMed ID: 23873119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of metformin.
    Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
    Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
    Cho SK; Chung JY
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
    Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
    Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
    J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.
    König J; Zolk O; Singer K; Hoffmann C; Fromm MF
    Br J Pharmacol; 2011 Jun; 163(3):546-55. PubMed ID: 20883471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
    Kimura N; Masuda S; Tanihara Y; Ueo H; Okuda M; Katsura T; Inui K
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):379-86. PubMed ID: 16272756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
    Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
    Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
    Song IS; Shin HJ; Shin JG
    Xenobiotica; 2008 Sep; 38(9):1252-62. PubMed ID: 18728938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
    Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
    Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
    Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
    Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
    Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.